Literature DB >> 65479

The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma.

J E Montie, B H Stewart, R A Straffon, L H Banowsky, C B Hewitt, D K Montague.   

Abstract

The results of therapy for 78 patients with disseminated renal cell carcinoma are evaluated. Symptoms related to the primary tumor were noted in only 28 per cent of the patients and were not difficult to manage in those patients not undergoing nephrectomy. Adjuctive nephrectomy, therefore, is a more appropriate term than palliative nephrectomy when referring to removal of the primary tumor as part of an aggresive combined therapeutic approach. Of patients receiving an adjunctive nephrectomy those with osseous metastases only had a better 1-year survival rate (36 per cent) than those with metastases to other sites (18 per cent). Complete regression of metastases was noted in 12 per cent of patients treated with medroxyprogesterone acetate and adjunctive nephrectomy. The role of adjunctive nephrectomy combined with embolic infarction, hormonal therapy, chemotherapy and/or immunotherapy is discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 65479     DOI: 10.1016/s0022-5347(17)58429-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  32 in total

Review 1.  Immunotherapy for renal carcinoma: theoretical basis and current standard of care.

Authors:  P A Vasey
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

Review 2.  The role of resection for patients with renal carcinoma.

Authors:  R C Flanigan; P M Yonover
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

3.  Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial.

Authors:  F Porzsolt; D Messerer; R Hautmann; A Gottwald; H Sparwasser; K Stockamp; W Aulitzky; J G Moormann; K Schumacher; H Rasche
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 4.  Local treatment of metastatic cancer--killing the seed or disturbing the soil?

Authors:  Scott C Morgan; Chris C Parker
Journal:  Nat Rev Clin Oncol       Date:  2011-06-07       Impact factor: 66.675

Review 5.  The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma.

Authors:  Antonio Romo de Vivar Chavez; Michael E de Vera; Xiaoyan Liang; Michael T Lotze
Journal:  Med Oncol       Date:  2009-01-16       Impact factor: 3.064

6.  Metastatic renal cell carcinoma (RCC): spontaneous regression, long-term survival and late recurrence.

Authors:  W de Riese; K Goldenberg; E Allhoff; C Stief; R Schlick; S Liedke; U Jonas
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

7.  Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy.

Authors:  T F Logan; B Banner; U Rao; M S Ernstoff; N Wolmark; T L Whiteside; L Miketic; J M Kirkwood
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

Review 8.  Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors.

Authors:  Vitaly Margulis; Christopher G Wood; Eric Jonasch; Surena F Matin
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

9.  Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma.

Authors:  Yosuke Yasuda; Yasuhisa Fujii; Takeshi Yuasa; Shinichi Kitsukawa; Shinji Urakami; Shinya Yamamoto; Junji Yonese; Shunji Takahashi; Iwao Fukui
Journal:  Int J Clin Oncol       Date:  2012-09-11       Impact factor: 3.402

10.  Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy.

Authors:  Alexander Kutikov; Robert G Uzzo; Aaron Caraway; Carl T Reese; Brian L Egleston; David Y T Chen; Rosalia Viterbo; Richard E Greenberg; Yu-Ning Wong; Jay D Raman; Stephen A Boorjian
Journal:  BJU Int       Date:  2009-11-17       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.